Doximity, Inc.
NYSE:DOCSMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $5.47B
- Beta
- 1.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.06
Volume 2.27M
Average 3.89M
DOCS EBITDA Margin
EBITDA as a percentage of revenue.
Doximity, Inc.NYSE: DOCS
EBITDA Margin · Q2 FY2027 · quarter ended Sep 2026
EBITDA Margin narrows to 25.2%
EBITDA Margin was 25.2% in Q2 FY2027, down 20.2 pp from a year earlier. On a trailing-twelve-month basis it was 31.7%, down 16.1 pp year over year. Over 3 fiscal years it widened by 6.8 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 15 analysts of 45.6% for the fiscal year ending Mar 2027, up from 41.0% in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- 25.2%-3.3 pp QoQ
- Last fiscal yearMar 2026
- 41.0%-1.2 pp YoY
- LTMSep 2026
- 31.7%-16.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -20.2 pp | +5.9 pp | +26.1 pp |
| 1 year | -1.2 pp | +4.6 pp | +5.8 pp |
| 3 years | +6.8 pp | +8.1 pp | +1.4 pp |
| 5 years | +15.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2026
- 41.0%
- Year-over-year change
- -1.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 41.0% | -1.2pp |
| FY2025 | 2025-03-31 | 42.2% | +3.9pp |
| FY2024 | 2024-03-31 | 38.3% | +4.1pp |
| FY2023 | 2023-03-31 | 34.2% | -0.4pp |
| FY2022 | 2022-03-31 | 34.7% | — |
EBITDA Margin vs competitors
How DOCS compares with its peers on the latest reported figures
- DOCS's LTM Sep 2026 EBITDA Margin of 31.7% is the 2nd highest of the 10 companies compared; the peer median is 21.5%.
- Its year-over-year change of -16.1 pp is the lowest of 10, against a peer median of +1.1 pp.
- Over three fiscal years its change of +6.8 pp compares with a peer median of +2.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jul 2026 | 36.3% | +4.4 pp | +17.3 pp | |
| LTM Sep 2026 | 31.7% | -16.1 pp | +6.8 pp | |
| LTM Jun 2026 | 29.7% | +14.5 pp | +2.7 pp | |
| LTM Jul 2026 | 26.3% | -3.0 pp | -8.9 pp | |
| LTM Jun 2026 | 24.2% | +1.1 pp | +3.6 pp | |
| LTM Jul 2026 | 21.5% | -5.5 pp | -0.8 pp | |
| LTM Jun 2026 | 18.4% | +21.9 pp | -42.3 pp | |
| LTM Jun 2026 | 15.1% | -1.9 pp | -7.7 pp | |
| LTM Sep 2026 | -7.2% | +1.0 pp | +64.5 pp | |
| LTM Sep 2026 | -34.5% | +4.7 pp | +98.7 pp | |
| Peer median (excluding DOCS) | 21.5% | +1.1 pp | +2.7 pp | |
Competitors are the stored peer set for DOCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 343.55M | 419.05M | 475.42M | 570.4M | 644.86M |
| Cost of Revenue | 39.79M | 53.49M | 50.67M | 55.87M | 70.33M |
| Gross Profit | 303.76M | 365.56M | 424.75M | 514.53M | 574.54M |
| Gross Margin | 88.4% | 87.2% | 89.3% | 90.2% | 89.1% |
| Research & Development | 62.35M | 80.19M | 81.98M | 93.04M | 130.7M |
| Selling, General & Admin | 127.88M | 160.27M | 170.96M | 191.38M | 228.92M |
| Operating Expenses | 190.23M | 240.45M | 260.88M | 286.73M | 359.62M |
| Depreciation & Amortization | 5.04M | 10.28M | 10.27M | 10.66M | 14.38M |
| EBITDA | 119.05M | 143.44M | 182.08M | 240.76M | 264.39M |
| EBITDA Margin | 34.7% | 34.2% | 38.3% | 42.2% | 41.0% |
| Operating Income | 113.54M | 125.11M | 163.88M | 227.8M | 214.92M |
| Operating Margin | 33.0% | 29.9% | 34.5% | 39.9% | 33.3% |
| Interest Income | 2.15M | 9.29M | 21.66M | 35.85M | 35.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 469K | 8.05M | 21.32M | 35.77M | 35.09M |
| Income Before Tax | 114.01M | 133.16M | 185.2M | 263.57M | 250.01M |
| Pre-Tax Margin | 33.2% | 31.8% | 39.0% | 46.2% | 38.8% |
| Income Tax Expense | (40.78M) | 20.34M | 37.62M | 40.39M | 53.95M |
| Net Income | 154.78M | 112.82M | 147.58M | 223.19M | 196.05M |
| Net Margin | 45.1% | 26.9% | 31.0% | 39.1% | 30.4% |
| EPS (Basic) | 0.81 | 0.58 | 0.78 | 1.19 | 1.05 |
| EPS (Diluted) | 0.70 | 0.53 | 0.72 | 1.11 | 0.98 |
| Weighted Avg Shares | 163.48M | 193.18M | 190.17M | 186.84M | 187.01M |
| Weighted Avg Shares (Diluted) | 191.02M | 213.43M | 205.73M | 201.21M | 199.05M |
Doximity, Inc.
NYSE:DOCS
Intrinsic Alpha fair value
Locked
Current Price
$30.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.